🇺🇸 FDA
Patent

US 12421236

Seven-membered heterocyclic derivative acting as KRAS G12C mutant protein inhibitor

granted A61PA61P35/00

Quick answer

US patent 12421236 (Seven-membered heterocyclic derivative acting as KRAS G12C mutant protein inhibitor) held by Medshine Discovery Inc. expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Medshine Discovery Inc.
Grant date
Tue Sep 23 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61P, A61P35/00